頭頸癌之標靶治療－Cetuximab

Head and Neck Cancer Target Therapy and Cetuximab

林秀雯(Shiou-Wen Lin)

《榮總護理》 27卷2期 (2010/06) Pp. 214-218

https://doi.org/10.6142/VGHN.27.2.214

摘要

全世界每年有超過五十萬以上人口被診斷出頭頸部的鱗狀細胞癌。在台灣地區，頭頸部鱗狀細胞癌發生的比例逐年增加，位居男性癌症死亡原因的第四名，主要的致病危險因子：抽菸、嚼食檳榔及酗酒。治療方法傳統上包括有手術移除、化學治療和放射線治療。隨著醫學的進步，新的治療方法持續被研究及發展。而目前腫瘤治療的發展趨勢為－標靶治療。標靶治療藥物在復發性或轉移性頭頸癌的治療研究上已開始有所突破，其中Cetuximab是屬於上皮生長因子接受器的抑制劑(epidermal growth factor receptor inhibitor, EGFR inhibitor)。為目前最常被使用來治療頭頸癌的標靶藥物，不僅對局部侵犯性頭頸癌有顯著的療效，對於復發性或轉移性頭頸癌也可單獨使用Cetuximab治療。

關鍵字

頭頸癌 ； 標靶治療 ； Cetuximab

並列摘要

More than a half million people are diagnosed with head and neck squamous cell carcinoma each year. In Taiwan, the proportion of squamous cell carcinoma is increasing and has become the fourth deadliest cancer among Taiwanese men. The main causes include smoking, alcohol abuse, and betel nuts chewing. The traditional methods of treating squamous cell carcinoma include surgery, chemotherapy and radiation therapy. With the progress of medical science however, new and effective treatment method are being developed, such as target therapy. The treatment research has already made progress in the recurrence or metastasis of head and neck cancer. Cetuximab is an epidermal growth receptor inhibitor, being currently the most common target medicine for the treatment of recurrent and metastatic squamous cell carcinoma of the head and neck

並列關鍵字

head and neck cancer ； target therapy ； Cetuximab